This clinical-stage biopharmaceutical company is studying the treatment of pediatric Crohn's Disease. It is also researching the treatment of patients with acute COVID-19 infection.
Investors should put STAB stock on their Watch Lists as biopharmaceutical companies performing clinical-stage research are rising in valuation
STAB PROCEEDS FROM REGISTERED OFFERINGS TO FUND STUDIES
Handley adds, "Following the recent submission to the FDA of our Phase 3 clinical trial protocol for STAT-201 in the treatment of pediatric Crohn's Disease, we plan to use proceeds from our registered direct offering to initiate patient enrollment in the second quarter."
Those dollars will also be used to add enrollment of patients with acute COVID-19 infection in its STAT-205 study. STAB hopes to develop preliminary data from that study this year.
STAB RELEASES 2021 FINANCIAL RESULTS
One catalyst for the company is its infrastructure building. Here are the highlights of its new financials:
- Volume increased 100% to
- Due to the acquisition, the cost of revenues related to the transaction was
- R&D expense rose in 2021 to
- The increase in R&D was a result of increased costs for the expanded clinical trial programs of Crohn's disease and COVID-19 in 2021.
- Other Expenses also rose for 2021 to
- Net loss for 2021 was
HANDLEY, STAB CEO, OPTIMISTIC ABOUT 2022 PERFORMANCE
"We have taken numerous steps to further the development of our clinical-stage pipeline that has us well-positioned to achieve numerous milestones in 2022," says
STAB is developing novel immunotherapies targeting autoimmune, neutropenia/anemia emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis.
STAB ADDS TO ITS BOARD
STAB has also added to its Board
"We are thrilled to welcome
Keep STAB stock on your
Disclaimers: TopNewsGuide 'TNG' is responsible for the production and distribution of this content. TNG is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The information made available by TNG is not intended to be, nor does it constitute, investment advice or recommendations. The contributors may buy and sell securities before and after any particular article, report and publication. In no event shall TNG. be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by TNG., including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information in this video, article, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. TNG. strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
CONTACT:
editor@topnewsguide.com
(754) 233-0966
.
(C) 2022 M2 COMMUNICATIONS, source